- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06835868
Neuro-Pain Provides a Dynamic and Interactive Register for the Invasvive Neuromodulatory Therapies for Different Chronic Pain Syndromes. Patients Living in Belgium and Suffering from Persistent Spinal Pain Syndromes Type 2 As Well As Suffering from Complex Regional Pain Syndromes Are Included.
February 27, 2025 updated by: University Hospital, Antwerp
Nationwide Dynamic Register for Screening, Evaluation and Follow-up of Patients Suffering from Chronic Pain Syndromes and Treated by Means of Invasive Neuromodulation.
Patients suffereing from chronic pain due to persistent spinal pain syndromes or complex regional pain syndromes and living in Belgium will be included in this register once they are being considered for a treatment with invasive neuromodulation (either spinal cord stimulation either dorsal root ganglion stimulation).
The screening process, the multidisciplinary evaluation, the trial therapy and the long-terl follow-up will be monitored through this register.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
7000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Guy H HANS, MD, PhD
- Phone Number: 4945 003238213000
- Email: guy.hans@uza.be
Study Contact Backup
- Name: Lisa Bernaerts
- Phone Number: 00323821300
- Email: lisa.bernaerts@uza.be
Study Locations
-
-
Antwerp
-
Edegem, Antwerp, Belgium, 2650
- Recruiting
- UZA, multidisciplinary pain center
-
Contact:
- Guy H Hans, MD, PhD
- Phone Number: 003238213000
- Email: pijncentrum@uza.be
-
Contact:
- Davina Wildemeersch, MD, PhD
- Email: davina.wildemeersch@uza.be
-
Contact:
- Guy H Hans, MD, PhD
-
Contact:
- Davina Wildemeersch, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adult patients suffering from chronic pain syndromes, either persistent spinal pain syndromes or complex regional pain syndromes.
Description
Inclusion Criteria:
- chronic pain syndromes
Exclusion Criteria:
- acute pain syndromes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain intensity after 21 days
Time Frame: 21 days
|
Follow-up of pain intensity (measured by the Numeric Rating Scale, with a minimum of 0 and a maximum score of 10) during the trial therapy of 21 days, together with quality of sleep and quality of ambulation (also ona NRS scale from 0 to 10).
|
21 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 14, 2018
Primary Completion (Estimated)
January 31, 2030
Study Completion (Estimated)
January 1, 2032
Study Registration Dates
First Submitted
February 14, 2025
First Submitted That Met QC Criteria
February 14, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
February 27, 2025
Last Verified
February 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Neuro-Pain
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.